AbstractThe octapeptide Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr (peptide T) and two structural analogs are potent agonists of human monocyte chemotaxis, evincing identical rank potency orders as was previously shown for their inhibition of human immunodeficiency virus (HIV) envelope binding and T cell infectivity. Chemotactic activity could be inhibited by anti-CD4 monoclonal antibodies (Mabs), but not other mononuclear cell Mabs. The core peptide required for chemotactic activity is a pentapeptide related to the sequence Thr-Thr-Asn-Tyr-Thr. Homologous pentapeptides, identified by computer search, were detected in several other non-HIV-related viruses as well as the neuropeptide vasoactive intestinal polypeptide (VIP). The CD4 molecule, therefore,...
AbstractPeptide T is currently in phase II clinical trials for the treatment of AIDS-associated deme...
The interaction between the viral envelope protein gp120 and the cellular surface antigen CD4 is a k...
Peptide T is currently in phase II clinical trials for the treatment of AIDS-associated dementia. It...
A five-amino-acid (TDNYT) sequence of vasoactive intestinal polypeptide (VIP) shares homology with t...
The octapeptide sequence of peptide T is contained within the envelope of HIV and seems to mediate t...
The octapeptide sequence of peptide T is contained within the envelope of HIV and seems to mediate t...
Acquired immunodeficiency syndrome (AIDS) is initiated by the attachment of the human immunodeficien...
Fifteen pentapeptide analogs of C-terminal fragment of peptide T, H-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-...
Fifteen pentapeptide analogs of C-terminal fragment of peptide T, H-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-...
Benzylated derivatives of a peptide (CD4(81-92)) representing the CDR3-like region of CD4 were previ...
The sequential interaction of the envelope glycoprotein of the human immunodeficiency virus type 1 (...
The octapeptide D-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-NH(2) ([D-Ala(1)]TNH(2)), an analog of peptide T (...
Liposomes can be targeted to HIV-infected cells by either reconstituting transmembrane CD4 in the me...
AbstractThe chemokine receptor CXCR4 interacts with a single endogenous chemokine, CXCL12, and regul...
Linear and head to tail cyclic hexapeptide analogs (Xaa-Thr-Thr-Asn-Tyr-Thr, Xaa = D-Asp or D-iso-As...
AbstractPeptide T is currently in phase II clinical trials for the treatment of AIDS-associated deme...
The interaction between the viral envelope protein gp120 and the cellular surface antigen CD4 is a k...
Peptide T is currently in phase II clinical trials for the treatment of AIDS-associated dementia. It...
A five-amino-acid (TDNYT) sequence of vasoactive intestinal polypeptide (VIP) shares homology with t...
The octapeptide sequence of peptide T is contained within the envelope of HIV and seems to mediate t...
The octapeptide sequence of peptide T is contained within the envelope of HIV and seems to mediate t...
Acquired immunodeficiency syndrome (AIDS) is initiated by the attachment of the human immunodeficien...
Fifteen pentapeptide analogs of C-terminal fragment of peptide T, H-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-...
Fifteen pentapeptide analogs of C-terminal fragment of peptide T, H-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-...
Benzylated derivatives of a peptide (CD4(81-92)) representing the CDR3-like region of CD4 were previ...
The sequential interaction of the envelope glycoprotein of the human immunodeficiency virus type 1 (...
The octapeptide D-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-NH(2) ([D-Ala(1)]TNH(2)), an analog of peptide T (...
Liposomes can be targeted to HIV-infected cells by either reconstituting transmembrane CD4 in the me...
AbstractThe chemokine receptor CXCR4 interacts with a single endogenous chemokine, CXCL12, and regul...
Linear and head to tail cyclic hexapeptide analogs (Xaa-Thr-Thr-Asn-Tyr-Thr, Xaa = D-Asp or D-iso-As...
AbstractPeptide T is currently in phase II clinical trials for the treatment of AIDS-associated deme...
The interaction between the viral envelope protein gp120 and the cellular surface antigen CD4 is a k...
Peptide T is currently in phase II clinical trials for the treatment of AIDS-associated dementia. It...